JPMorgan Chase Sells Stake in Bio-Techne Corp

Biotechnology company sees major institutional investor reduce position

Mar. 22, 2026 at 8:49am

Got story updates? Submit your updates here. ›

JPMorgan Chase & Co. has lowered its stake in Bio-Techne Corp (NASDAQ:TECH) by 46.6% during the 3rd quarter, according to a recent SEC filing. The firm sold 633,738 shares of the biotechnology company's stock, leaving it with 725,085 shares worth approximately $40.3 million.

Why it matters

Bio-Techne is a major player in the biotechnology industry, developing and manufacturing high-quality reagents, instruments, and services for research, diagnostic, and bioprocessing markets. The reduction in JPMorgan Chase's position could signal a shift in investor sentiment around the company or the broader biotech sector.

The details

According to the filing, JPMorgan Chase & Co. now owns about 0.47% of Bio-Techne's outstanding shares. The sale comes as other major institutional investors, including Wellington Management Group, American Century Companies, and Neuberger Berman Group, have increased their positions in the company.

  • JPMorgan Chase & Co. lowered its stake in Bio-Techne during the 3rd quarter of 2026.

The players

JPMorgan Chase & Co.

A multinational investment bank and financial services company headquartered in New York City.

Bio-Techne Corp

A global life sciences company that develops, manufactures, and sells high-quality reagents, instruments, and services for the research, diagnostic, and bioprocessing markets.

Got photos? Submit your photos here. ›

The takeaway

The reduction in JPMorgan Chase's stake in Bio-Techne could be a sign of broader shifts in the biotechnology industry, as major institutional investors adjust their portfolios. However, the company continues to attract interest from other large investors, suggesting its core business and products remain attractive to the market.